SCHIZOPHRENIA

This study looks at whether adding metformin to statin treatment can prevent or reduce blood sugar issues in people with schizophrenia. Statins are used to lower cholesterol but can raise diabetes risk. The trial will give 400 participants either metformin or a placebo alongside …

This study tests whether adding brenipatide to standard schizophrenia medication is safe and effective. About 450 adults with schizophrenia will receive either brenipatide or a placebo for up to 12 months. The main goals are to see if it helps with weight management, thinking ski…

This study checks the long-term safety of an experimental drug called NBI-1117568 in 600 adults with schizophrenia. Participants must stop taking other antipsychotic medications before joining. The main goal is to track any side effects that occur during treatment.

This study looks at the long-term safety of an experimental drug called KarXT when added to standard antipsychotic treatment for adults with schizophrenia whose symptoms are not well controlled. About 280 participants who completed a previous study will take KarXT for up to 52 we…

This study tests a community-based cognitive remediation program for 160 adults with schizophrenia or schizoaffective disorder. Participants do computer exercises and group sessions to improve memory, problem-solving, and social skills. The goal is to see if this helps them think…

This study tests an experimental drug called NBI-1117568 to see if it can delay or prevent the return of schizophrenia symptoms in adults who are stable on the drug. About 560 participants will first receive the drug openly, then be randomly assigned to continue the drug or switc…

This study compares standard coordinated specialty care (CSC) to an enhanced version (CSC 2.0) that adds peer support, digital outreach, care coordination, family therapy, and cognitive training. About 350 people with first-episode psychosis will take part. Researchers want to se…

This study tests an experimental drug called NBI-1117568 to see if it improves schizophrenia symptoms better than a placebo. About 284 adults who are hospitalized for a schizophrenia flare-up will take the drug or a dummy pill for 5 weeks. The main goal is to measure changes in s…

This study follows 1500 adults with schizophrenia who are starting a new medication called KarXT (xanomeline and trospium chloride). Researchers want to see how well it works in everyday life, including side effects, weight changes, and whether it reduces hospital visits. The goa…

This study tests whether a non-invasive brain stimulation technique called tDCS can help people with schizophrenia reduce their cannabis use. Researchers will give 110 participants 10 sessions of stimulation targeting brain areas linked to control and reward. The goal is to see i…

This study looks at how KarXT, a medication for schizophrenia, affects bladder function and overall safety. About 60 adults with schizophrenia will take KarXT for 12 months while doctors monitor their urination and any side effects. The goal is to understand the drug's safety, no…

This study tests a new way to start olanzapine, a standard schizophrenia medication, to see if it is safer and works as well. About 120 adults with schizophrenia will receive either the new dosing schedule or the usual one. The goal is to better control symptoms while reducing si…

This study tests magnetic seizure therapy (MST) as a gentler alternative to electroconvulsive therapy (ECT) for people with treatment-resistant schizophrenia. About 80 adults with schizophrenia or schizoaffective disorder who have not responded to at least two antipsychotics will…

This study is testing the long-term safety and tolerability of an experimental drug called ML-007C-MA in 500 adults with schizophrenia. Participants will take the drug for up to 52 weeks to see how well it works and what side effects may occur. The study is for people who have al…

This study tests the long-term safety of a new drug called SEP-363856 in 100 adults with stable schizophrenia. Participants take either 75 mg or 100 mg daily for 52 weeks. The main goal is to see what side effects occur. This is not a cure, but aims to help control the disease wi…

This study tests whether valbenazine can reduce involuntary muscle movements in people with tardive dyskinesia who still have symptoms despite prior treatment. About 50 adults with schizophrenia, bipolar disorder, or major depression will take valbenazine for 24 weeks. The goal i…

This study tests whether tirzepatide, a drug used for diabetes and obesity, can reduce heavy drinking in people who have both schizophrenia and alcohol use disorder. About 108 participants will receive either tirzepatide or a placebo for 16 weeks. Researchers will track drinking …

This study is checking the long-term safety of a drug called KarXT (and a version called KarX-EC) in teenagers with schizophrenia and in children aged 5 to 17 with irritability linked to autism. About 400 participants who finished a prior study will take the drug and be monitored…

This study tests a program called Taking Action, where trained peers help college students with serious mental illnesses like depression, bipolar disorder, or schizophrenia learn to manage their condition. About 300 students will be randomly assigned to either the program or just…

This study tests whether clozapine, a medication for schizophrenia, can reduce violent acts better than standard treatments. It involves 280 adults with schizophrenia or schizoaffective disorder who have been violent in the past six months. Participants will receive either clozap…

This study is testing whether the antipsychotic clozapine works better than risperidone for people with a specific brain-based subtype (Biotype-1) of psychosis. About 524 adults with schizophrenia, schizoaffective disorder, or bipolar I disorder with psychosis will take either cl…

This study explores whether some cases of schizophrenia or schizoaffective disorder are actually caused by the immune system attacking the brain. Researchers are giving an immune-suppressing drug called ocrelizumab to 40 adults aged 18-35 who developed psychosis after age 15. The…

This study tests whether regular electroconvulsive therapy (ECT) sessions, given over time, can prevent a return of symptoms in people with schizophrenia that did not improve with the strongest medications. About 140 adults who already improved with a short course of ECT will eit…

This study tests a long-acting injection of cariprazine given once a month under the skin. It is for people with schizophrenia, bipolar I disorder, or major depressive disorder who are stable on other medications. The goal is to check safety, how the drug moves in the body, and i…

This study compares a new version of a long-acting schizophrenia medication (paliperidone injection given every 3 months) to the approved drug Invega Trinza. About 260 Chinese adults with stable schizophrenia will receive multiple doses to see if the new formulation works similar…

This study tests a drug called KarXT in 166 teenagers (13-17 years old) with schizophrenia. The goal is to see if KarXT safely reduces symptoms like hallucinations and confusion compared to a placebo. Participants will take the drug or a dummy pill for several weeks, and doctors …

This study tests whether a long-acting injection of iloperidone can prevent schizophrenia symptoms from getting worse compared to a placebo. About 400 adults aged 18 to 65 with schizophrenia will receive either the drug or a placebo injection and be monitored for how long it take…

This study tests whether cariprazine, a medicine already used in adults, can safely reduce schizophrenia symptoms in teenagers aged 13 to 17. About 330 teens will receive either cariprazine or a placebo for 6 weeks. The main goal is to see if symptoms improve more with the active…

This study tests whether a personalized form of brain stimulation, called iTBS, can help reduce symptoms of schizophrenia. Forty adults with schizophrenia will receive daily stimulation sessions for two weeks, while continuing their usual medications. Researchers will measure cha…

This study tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) can improve cognitive problems and mood in people with schizophrenia, autism, bipolar disorder, depression, or Parkinson's disease. Researchers will give TMS to the …

This study tests whether a low dose of buprenorphine (0.15 mg) can improve social motivation in 40 adults with schizophrenia. Social withdrawal is a major problem for many patients, and no approved medications exist for it. Participants will take either the drug or a placebo in t…

This study tests whether metformin, a common diabetes medication, can improve memory and thinking in people with schizophrenia. Researchers will give 120 participants either metformin or a placebo for 24 weeks and measure changes in cognitive tests and brain scans. The goal is to…

This study tests a 12-session group program called "Better Together" for 20 single adults with severe mental illness (like schizophrenia or bipolar disorder). The program teaches communication and emotional skills to help them form healthy romantic relationships. Participants wil…

This study tests whether a daily synbiotic (probiotic plus fiber) supplement can reduce symptoms like hallucinations and social withdrawal in people with schizophrenia or schizoaffective disorder. About 68 adults will take either the supplement or a placebo for several weeks, whi…

This early-stage study tests a new drug called VV119 in healthy adults and people with schizophrenia. The main goal is to check safety and how the drug moves through the body. About 40 participants will take multiple doses to see if the drug is well-tolerated.

This study tests a new smartphone app that uses games and stories to help people with schizophrenia improve their thinking, mood, and daily life skills. About 84 hospitalized adults will use the app for several weeks. The goal is to see if this fun approach works better than stan…

This study tests a program called Motivation Skills Training (MST) to help people with schizophrenia or schizoaffective disorder improve motivation and reach personal goals. About 80 adults will be randomly assigned to either MST or a healthy behaviors group for 12-14 weeks. Rese…

This study looks at whether cognitive behavioral therapy (CBT) can help veterans with serious mental illness (like schizophrenia or bipolar disorder) who also have chronic low back pain. About 190 veterans will receive CBT and be monitored for changes in pain interference, qualit…

This study tests whether a special motion-sensing video game can improve thinking and memory in people with schizophrenia. About 84 adults with stable symptoms will play the game for 2 months. Researchers will measure changes in cognitive skills using standard tests.

This study tests whether a new combination drug (OLZ/SAM) causes less weight gain than the standard drug olanzapine in teenagers with schizophrenia or bipolar I disorder. About 220 teens aged 10 to 17 will take either OLZ/SAM or olanzapine for up to 52 weeks. The main goal is to …

This study tests whether a non-invasive brain stimulation technique called high-frequency transcranial alternating current stimulation (Hi-tACS) can improve cognitive problems like memory and attention in people with schizophrenia. About 100 adults with stable schizophrenia will …

This study is for people with schizophrenia that hasn't improved with standard treatments, including clozapine. Researchers want to see if adding an anti-inflammatory drug to an NMDA-enhancing agent can improve thinking and memory. About 80 participants will take the combination …

This study looks at whether yoga-based exercises can improve community functioning—like socializing, working, and daily living skills—in veterans with severe mental illness (schizophrenia, schizoaffective disorder, or bipolar 1). About 112 veterans will be randomly assigned to ei…

This study looks at whether a prebiotic supplement can reduce inflammation and improve thinking skills in people with schizophrenia or schizoaffective disorder. Researchers will give the prebiotic to 60 adults aged 18-60 who are stable on antipsychotic medication. The goal is to …

This study tests whether adding a second drug that boosts NMDA receptors can improve schizophrenia symptoms better than a sigma-1 receptor agonist alone. About 90 adults with schizophrenia who have not responded well to at least two standard antipsychotics will take part. The mai…

This study tests an experimental drug called NBI-1117570 to see if it can improve schizophrenia symptoms like confusion, mood, and behavior. About 120 adults aged 18-55 who are currently in the hospital for a schizophrenia flare-up will take either the drug or a placebo for 35 da…

This early-stage study is testing a long-acting injectable form of KarXT in 48 people with schizophrenia. The main goal is to check safety and how the drug moves through the body. Researchers will give a single shot and monitor participants for side effects and drug levels.

This study tests whether people with schizophrenia who still hear voices despite medication can learn to quiet those voices using real-time brain scans (fMRI). Participants will be split into two groups: one gets real feedback on their brain activity, the other gets fake feedback…

This study tests an experimental drug, emraclidine, in about 268 adults with schizophrenia. The goal is to see if it safely reduces symptoms like hallucinations and confused thinking. Participants take the drug or a placebo for up to 42 days and are monitored closely. The trial i…

This study tests whether a noninvasive brain stimulation technique called iTBS can improve working memory and brain activity in people with early-stage schizophrenia. Researchers will use magnetic pulses and EEG to measure changes in the prefrontal cortex. 75 participants aged 18…

This study tests whether MDMA (the active ingredient in ecstasy) is safe and tolerable for people with schizophrenia. The goal is to see if it can improve social motivation, a common and hard-to-treat symptom. Twenty participants will receive increasing doses of MDMA in a control…

This study tests whether the drug KarXT can safely reduce symptoms of schizophrenia in Japanese adults experiencing an acute episode. About 250 participants will first receive either KarXT or a placebo for 5 weeks, then everyone can receive KarXT for a year. The goal is to see if…

This study looks at whether a drug that enhances NMDA receptor function can reduce negative symptoms (like low motivation and social withdrawal) in people with schizophrenia. Researchers want to see if the drug works differently for men and women. About 90 adults with stable schi…

This study tests a drug that boosts NMDA activity as a standalone treatment for schizophrenia. It is for people who refuse or cannot take standard antipsychotics due to side effects or poor response. The trial will measure changes in symptoms like hallucinations and social withdr…

This study tests whether a smartphone app called Kiso Mind is acceptable and practical for people with schizophrenia or schizoaffective disorder. About 60 participants will either use the app plus their usual care, or just usual care, for 12 weeks. The main goal is to see if peop…

This study tests whether cromoglicate, a drug used for allergies, can improve symptoms of schizophrenia when taken alongside standard antipsychotic medication. About 160 adults with schizophrenia or schizoaffective disorder will receive either cromoglicate or a placebo for severa…

This study tests a new drug, ALTO-101, given through a skin patch, to see if it helps with thinking and memory problems in people with schizophrenia. About 82 adults with stable schizophrenia and cognitive issues will receive either the drug or a placebo, then switch. The main go…

This study tests whether breathing extra oxygen (normobaric oxygen therapy) can improve thinking, quality of life, and daily functioning in people who have had psychosis for less than 5 years. Twenty participants aged 15-35 with a schizophrenia-spectrum or mood disorder with psyc…

This study tests a new medication, LB 102, to see if it can reduce symptoms of schizophrenia in adults experiencing a sudden worsening of their condition. About 456 participants will receive either LB 102 or a placebo for 6 weeks. The goal is to measure changes in symptom severit…

This early-stage study tests a new extended-release tablet called LY03020 in healthy adults and people with stable schizophrenia. The main goal is to check safety and how the body processes the drug. About 40 participants will receive either the drug or a placebo, and researchers…

This study tests an experimental oral medication, ML-007C-MA, against a placebo in 300 adults hospitalized for a sudden worsening of schizophrenia symptoms. The goal is to see if the drug safely reduces psychosis severity, measured by a standard symptom scale. Participants must b…

This study tests a therapy called Targeted Cognitive Training (TCT) for 80 veterans with serious mental illnesses like schizophrenia, bipolar disorder, or PTSD. TCT uses computer exercises to improve how the brain processes sounds and information. Researchers will use EEG brain s…

This study tests whether BXCL501 can safely reduce agitation in children aged 10-17 with schizophrenia or bipolar disorder. Participants receive either the drug or a placebo, and researchers measure changes in agitation using a standard rating scale. The trial is currently recrui…

This study tests whether a non-invasive brain stimulation technique called navigated transcranial magnetic stimulation (nTMS) can reduce negative symptoms of schizophrenia, such as lack of motivation, social withdrawal, and reduced speech. Forty adults with schizophrenia will rec…

This study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) can help people with schizophrenia quit or reduce smoking. Fifty participants will receive active rTMS using either an F8 coil or an H coil. Researchers …

This study tests whether a new drug called GXV813 can safely reduce symptoms of schizophrenia during an acute episode. About 142 hospitalized adults aged 18-65 will receive either GXV813 or a placebo. The main goal is to see if the drug improves scores on a standard symptom scale…

This study tests a new medication called Ulotaront (SEP-363856) to see if it can safely reduce severe symptoms like hallucinations and delusions in people with schizophrenia. About 522 adults experiencing an acute psychotic episode will receive either the drug or a placebo for 6 …

This study tests a new medicine called NBI-1117568 to see if it can improve schizophrenia symptoms better than a placebo. About 284 adults with schizophrenia who need hospital care will take part. The main goal is to measure changes in symptoms like hallucinations and delusions a…

This study tests whether adding acetazolamide to standard antipsychotic medication can reduce symptoms in people with treatment-resistant schizophrenia. About 60 adults aged 18-55 will receive either acetazolamide or a placebo for a set period, while continuing their usual medica…

This study looks at whether safely stopping unnecessary anticholinergic drugs (like benztropine) can improve thinking, daily function, and quality of life in people aged 40-70 with schizophrenia or schizoaffective disorder. Participants will either continue their medication or gr…

This study tests whether a non-invasive brain stimulation technique called TMS, applied to the cerebellum, can improve brain connectivity and thinking skills in people with schizophrenia. Forty adults aged 18-60 will receive either real or sham TMS daily for four weeks, alongside…

This study tests whether real-time brain imaging (fMRI) can help people with schizophrenia learn to quiet the auditory hallucinations (hearing voices) that don't respond to medication. Participants will receive neurofeedback training to reduce activity in a brain area linked to v…

This study tests a virtual reality program designed to help people with psychosis improve their thinking and social skills. About 52 adults aged 18-60 with stable psychosis will use the program and do homework. The goal is to see if it's practical and helpful for daily life.

This study uses PET brain scans to measure cannabinoid receptors in healthy volunteers and people with conditions like schizophrenia, cannabis dependence, PTSD, and opioid use disorder. Researchers aim to understand how these receptors differ across groups and how they change wit…

This study uses MRI scans to understand why people with schizophrenia hear voices that aren't there. Researchers think a small brain area called the inferior colliculi may fail to filter out internal sounds. 40 participants with schizophrenia will have their brain activity measur…

This study is testing a new job training program that uses virtual reality to help people with schizophrenia improve their job interview skills. About 40 adults aged 20 to 55 who are stable and motivated to work will take part. The goal is to see if the program can boost their ab…

This study is observing 300 adults with schizophrenia in the U.S. who are prescribed a new medication called KarXT (xanomeline and trospium chloride). Researchers want to learn how satisfied patients are with the treatment and which medication they prefer. No new treatment is giv…

This study uses powerful 7T MRI brain scans and visual perception tests to find biological markers that could improve diagnosis and treatment for severe mental disorders like major depression, schizophrenia, and bipolar disorder. Researchers will compare 320 patients and healthy …

This study uses a safe, noninvasive brain stimulation technique called TMS to learn how hallucinations happen in people with schizophrenia or schizoaffective disorder. Researchers will measure brain activity and symptom changes in 68 participants before and after TMS. The goal is…

This study looks at how feeling lonely and being socially isolated affect the brain and daily life in people with serious mental illness like psychosis or schizophrenia. Researchers will use surveys, daily check-ins, and brain scans to understand these connections. The goal is to…

This study compares brain energy use, lactate, and glutamate levels between 75 people with schizophrenia and healthy volunteers. Participants undergo MRI and PET scans to measure brain activity and chemistry. The goal is to better understand how the brain works in schizophrenia, …

This study tests whether a non-invasive brain stimulation technique called tDCS can improve executive functions—like memory, attention, and self-control—in people with conditions such as traumatic brain injury, depression, bipolar disorder, schizophrenia, ADHD, borderline persona…

This study looks at how a part of the brain called the thalamus helps us switch between tasks and adapt to new situations. Researchers will use powerful MRI scans to watch brain activity while 100 healthy adults perform thinking tasks. The goal is to learn more about why people w…

This study tests whether a non-invasive brain stimulation technique called accelerated TMS can improve thinking and memory in people with schizophrenia or schizoaffective disorder who are already taking the medication clozapine. Thirty participants will receive both real and sham…

This study looks for early signs that a person having their first psychotic episode will not get better with standard treatment. Researchers will use brain imaging to find markers that predict poor response by month 3. The goal is to identify these patients sooner so they can rec…

This study looks at whether a gentle brain stimulation technique called tDCS changes the number of connections between brain cells in people with schizophrenia. Researchers will use special PET scans to measure these connections before and after treatment. The goal is to better u…

This study is testing a new social skills training program designed to help veterans with serious mental illness (like schizophrenia, bipolar disorder, or PTSD) improve their work relationships and job success. About 20 veterans will take part in weekly group sessions and practic…

This study looks at whether cognitive remediation—a type of brain training with coaching—can improve thinking skills, daily function, and behavior in people staying in a forensic mental health unit. About 30 adults with conditions like psychosis, ADHD, or substance use will take …

This study explores whether precise brain stimulation can lower cannabis cravings in people with schizophrenia or schizoaffective disorder. Researchers will use a type of magnetic stimulation (rTMS) on specific brain areas and measure changes in cravings and brain activity. The g…

This study aims to better understand high-level thinking problems—like motivation, self-awareness, and decision-making—in people with mental health or brain disorders such as schizophrenia, depression, bipolar disorder, Alzheimer's, and stroke. Researchers will compare 600 patien…

This study aims to understand how different parts of the brain's prefrontal cortex control behaviors in people with major depression, obsessive-compulsive disorder, generalized anxiety disorder, or schizophrenia. Participants will receive transcranial magnetic stimulation (TMS) a…

This study looks at language difficulties in people with psychosis, including those with schizophrenia or early warning signs. Researchers will give language tests to 90 patients and compare results with healthy controls. The goal is to understand how language problems connect wi…

This study looks at 200 children and teens (ages 7-20) who have had a psychotic episode, such as in schizophrenia. Researchers will use interviews, brain scans, and genetic tests to group participants by their symptoms. The goal is to see if these groups can predict which antipsy…

This study is testing whether a type of brain stimulation called repetitive TMS can increase natural inhibition in the brain of people with schizophrenia. Thirty-four adults with schizophrenia will receive five days of low-frequency magnetic pulses over the motor cortex. The main…

This study uses fun virtual reality games to measure how people with schizophrenia or bipolar disorder experience the passage of time. Researchers will compare 120 participants (patients and healthy volunteers) using brain wave recordings (EEG) and reaction times. The goal is to …

This study aims to find biological markers in people with treatment-resistant schizophrenia who respond to the drug clozapine. Researchers will examine 200 participants before and after 12 weeks of clozapine treatment, looking at immune markers, brain scans, and spinal fluid. The…

This study collects brain scans and thinking tests from 1,000 people with schizophrenia, schizoaffective disorder, and healthy volunteers. Researchers want to see how brain areas work differently during memory tasks. The goal is to better understand mental disorders, not to test …

This study looks at how attention and thinking strategies influence decision-making and brain activity in people with schizophrenia or schizoaffective disorder compared to healthy volunteers. Researchers will train participants to use a positive thinking strategy and then measure…

This study looks at whether a non-invasive brain stimulation technique called TMS can improve how quickly people with psychotic disorders (like schizophrenia or bipolar disorder) solve problems. About 95 participants will do thinking tasks and get brain scans before and after TMS…

This study tests whether a safe, non-invasive technique called transcranial direct current stimulation (tDCS) can improve attention, learning, and memory in people with schizophrenia. Researchers will give a tiny electrical current to the forehead and measure brain activity and n…

This study looks at how people with schizophrenia experience time and sensory information differently. Researchers will use a visual illusion to test if small delays in what we see disrupt the flow of time for patients. The goal is to better understand the unusual experiences tha…

This study looks at how people with schizophrenia use the passage of time to predict and prepare for a touch sensation. Researchers will measure finger movements and brain signals to find objective markers of time perception problems. The goal is to develop a test that could help…

This study looks at 300 people with first-episode schizophrenia (who haven't taken medication yet) and healthy volunteers. Researchers will examine tiny particles called exosomes in the blood to see if their microRNA content is linked to cognitive (thinking) problems. The goal is…

This study looks at 320 people who recently developed psychosis (like schizophrenia or bipolar I) to see if brain scans, eye-tracking, and genetics can predict who will get better with treatment. Participants attend four visits over a year, providing DNA, EEG, and MRI data. The g…